In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...

A spin-out from the University of Edinburgh in Scotland is already equipped with 15 million pounds ($19 million) in seed ...

Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for ...

Disease markers stabilized or improved in cardiomyopathy patients who received a single dose of Intellia Therapeutics’ in ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

Philips has secured an FDA clearance for what it describes as the world’s first imager to combine spectral CT with ...

Last month, the NIH announced that it had found evidence of research misconduct by Eliez | This week on "The Top Line," we ...

The two companies have been working together since 2017, and, in 2021, they agreed to collaborate on NM26, a bispecific ...

Two industry veterans are taking the reins at Apriori Bio and Valo Health, biotechs backed by VC firm Flagship Pioneering. Craig Williams has been promoted to CEO-partner at Flagship and is now CEO of ...

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes in a midphase trial, positioning the biotech to advance the ex-Novartis ...